Newsroom

Verantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen

News

The issue of best price is one of the most frequently cited regulatory obstacles to value-based arrangements such as outcomes-based contracts.

Read at the original outlet
All news
Get started

Ready to advance your evidence program?

Speak with our team about how the Verantos pharmacoepidemiology stack can accelerate your timeline.